Tianjin Saide Medicine

Tianjin Saide Biopharmaceutical is a Chinese biotechnology company focused on the development of long-acting recombinant protein therapeutics. The company's core expertise lies in its proprietary protein fusion platform, which it uses to enhance the half-life and efficacy of established biologic agents. Its lead product candidate is a recombinant human serum albumin-interferon alpha 2b fusion protein, currently being evaluated in clinical trials for the treatment of chronic hepatitis B and C. By utilizing human serum albumin as a carrier, the company aims to provide a more stable and less immunogenic alternative to pegylated interferons. Based in the Tianjin Binhai New Area, Tianjin Saide operates integrated facilities for research, development, and pilot-scale manufacturing. The company is positioned to address significant public health challenges in China, particularly in the field of viral infectious diseases.